Birdwatch Archive - Rating Details

Birdwatch Note Rating

2023-07-11 17:27:51 UTC - HELPFUL

Rated by Participant: 26C9A36A244E5C651367822942E8295EE7E7A4D34C46CB7C7C9F9CD1EC8F79CF
Participant Details

Original Note:

The Phase 3 LUCIDITY trial for hydromethylthionine mesylate (HMTM) failed to meet its endpoint as reported on Medscape. Additional trials are underway. The LUCIDITY trial did have encouraging results that TauRx Pharmaceuticals are promoting through PR releases. https://www.prnewswire.com/in/news-releases/lucidity-phase-3-topline-data-presented-at-ctad-for-hmtm--the-only-oral-anti-tau-therapy-in-late-stage-development-301690475.html https://www.medscape.com/viewarticle/984863 https://archive.is/awWDp

All Note Details

Original Tweet

All Information

noteId - 1677803233077522432
participantId -
raterParticipantId - 26C9A36A244E5C651367822942E8295EE7E7A4D34C46CB7C7C9F9CD1EC8F79CF
createdAtMillis - 1689096471795
version - 2
agree - 0
disagree - 0
helpful - 0
notHelpful - 0
helpfulnessLevel - HELPFUL
helpfulOther - 0
helpfulInformative - 0
helpfulClear - 0
helpfulEmpathetic - 0
helpfulGoodSources - 1
helpfulUniqueContext - 0
helpfulAddressesClaim - 0
helpfulImportantContext - 1
helpfulUnbiasedLanguage - 0
notHelpfulOther - 0
notHelpfulIncorrect - 0
notHelpfulSourcesMissingOrUnreliable - 0
notHelpfulOpinionSpeculationOrBias - 0
notHelpfulMissingKeyPoints - 0
notHelpfulOutdated - 0
notHelpfulHardToUnderstand - 0
notHelpfulArgumentativeOrBiased - 0
notHelpfulOffTopic - 0
notHelpfulSpamHarassmentOrAbuse - 0
notHelpfulIrrelevantSources - 0
notHelpfulOpinionSpeculation - 0
notHelpfulNoteNotNeeded - 0
ratingsId - 167780323307752243226C9A36A244E5C651367822942E8295EE7E7A4D34C46CB7C7C9F9CD1EC8F79CF